Australia (AU)

HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer (2020) Brunton H, Caligiuri G, Cunningham R, Upstill-Goddard R, Bailey UM, Garner IM, Nourse C, et al. Journal article Phenotypic spectrum and transcriptomic profile associated with germline variants in TRAF7 (2020) Castilla-Vallmanya L, Selmer KK, Dimartino C, Rabionet R, Blanco-Sanchez B, Yang S, Reijnders MRF, et al. Journal article Solving the preoperative breast MRI conundrum: design and protocol of the MIPA study (2020) Sardanelli F, Trimboli RM, Houssami N, Gilbert FJ, Helbich TH, Alvarez Benito M, Balleyguier C, et al. Journal article Deep XMM-Newton observations of the northern disc of M31 (2020) Kavanagh PJ, Sasaki M, Breitschwerdt D, De Avillez MA, Filipovic MD, Galvin T, Haberl F, et al. Journal article Optically-Induced Antiferromagnetic Order in Mie-Resonant Dielectric Metasurfaces (2020) Zhou W, Choi DY, Sautter J, Arslan D, Zou C, Fasold S, Lepeshov S, et al. Conference contribution Brief recommendations for participation in leisure time or competitive sports in athletes–patients with coronary artery disease: Summary of a Position Statement from the Sports Cardiology Section of the European Association of Preventive Cardiology (EAPC) (2020) Borjesson M, Dellborg M, Niebauer J, Lagerche A, Schmied C, Solberg EE, Halle M, et al. Journal article Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study (2020) Bretana NA, Gray RR, Cunningham EB, Betz-Stablein B, Ribeiro R, Graw F, Luciani F, Lloyd AR Journal article The BCMA:Tomato Mouse - a new reporter to characterize long-lived plasma cells (2020) Schulz S, Wittner J, Kueh AJ, Pal M, Herold MJ, Schuh W, Jäck HM Conference contribution Chemical Reactions-based Detection Mechanism for Molecular Communications (2020) Cao TN, Jamali V, Wicke W, Yeoh PL, Zlatanov N, Evans J, Schober R Conference contribution Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3) (2020) Fasching P, Neven P, Jerusalem G, Beck JT, Chan A, De Laurentiis M, Bianchi GV, et al. Conference contribution